Ultragenyx Pharmaceutical Inc预计2026年现有产品总收入将达7.3亿至7.6亿美元

美股速递
Feb 13

生物制药公司Ultragenyx Pharmaceutical Inc近日发布业绩展望,预计到2026年,其现有产品线带来的总收入将达到7.3亿至7.6亿美元区间。这一预测凸显了公司核心产品的市场增长潜力。

该营收预期反映了公司对现有疗法商业化进程的充分信心。通过持续拓展适应症范围与优化市场渗透策略,Ultragenyx正稳步推进其罕见病治疗产品的全球布局。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10